Leukemia-associated antigens from autologous AML lysate presented on MHC molecules (LAA-AML-MHC)

Leukemia-associated antigens (LAAs) from autologous AML lysates consist of a diverse array of peptides derived from a patient's own leukemic cells, including shared antigens like WT1 and Proteinase 3, as well as patient-specific neoantigens (PMID: 19095938). These antigens are processed and presented on Major Histocompatibility Complex (MHC) Class I and II molecules to initiate a robust, polyclonal immune response (PMID: 21639181). This target is primarily utilized in the development of autologous dendritic cell (DC) vaccines, where DCs are 'pulsed' with the lysate to prime T-cells against the leukemia (ClinicalTrials.gov: NCT00016237). By targeting a broad spectrum of antigens simultaneously, this approach seeks to minimize the risk of immune escape caused by antigen loss, a common challenge in single-antigen therapies (PMID: 25533034). The biological goal is the induction of long-term immunosurveillance to eradicate minimal residual disease and prevent relapse in AML patients (PMID: 28104689). Therapeutic interaction involves the activation of cytotoxic T-lymphocytes that recognize these specific MHC-peptide complexes on the surface of malignant blasts, leading to targeted cell lysis.

Other names

Autologous AML lysate antigensAML-associated antigensTumor-associated antigens from AML lysateMHC-presented AML peptidesAutologous tumor lysate-derived antigens

Induction of a polyclonal T-cell response (CD4+ and CD8+) against a broad spectrum of patient-specific and shared leukemia-associated antigens presented on MHC molecules to eliminate residual leukemic cells (PMID: 21639181).